Posted by Michael Wonder on 15 Jul 2022
UK lags behind EU in authorising new medicines after Brexit
14 July 2022 - Experts attribute shortfall to small size of British market now it is regulated separately and complexity of dealing with NHS.
The UK fell behind the EU in the race to attract innovative medicines for use in the country in the first year after Brexit, researchers have found.
An audit of approvals issued by the UK’s medicines regulator conducted by Imperial College London found that only 35 so-called novel medicines were approved for use in the UK in 2021 compared with 40 in the EU and 52 in the US.
